Effect of anti-TNF-alpha therapy on endothelial progenitor cells and endothelial dysfunction in patients with psoriasis without risk factors for atherosclerosis - EPPSOR-Studie
Phase 1
- Conditions
- Psoriasis vulgaris
- Registration Number
- EUCTR2009-011397-14-DE
- Lead Sponsor
- Technical University of Dresden
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
- Patients aged between 18 and 50 years. The aim of this age restiction is to emphasize that the study population is propably not affected by common arteriosclerosis because of their age.
- Moderate to severe chronic plaque psoriasis (PASI = 10, BSA = 10, DLQI = 10)
- Indication for therapy with etanercept
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- Conventional cardiovascular risk factors
- Contraindication for etanercept, accordingly to the approved guidelines
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method